Arrowhead Pharmaceuticals (ARWR) Receivables - Net (2010 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly Receivables - Net came in at $15.7 million in Q1 2026, up 563.21% YoY from $2.4 million in Q1 2025, and down 92.82% on a QoQ basis from $218.4 million in Q4 2025.
Arrowhead Pharmaceuticals (ARWR) Receivables - Net (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 15 years of Receivables - Net data on file, last reported at $15.7 million in Q1 2026.
- Quarterly Receivables - Net rose 563.21% year-over-year to $15.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.7 million (up 563.21% YoY) and the FY2025 annual result came in at $6.8 million, changed N/A from the prior year.
- Receivables - Net slipped to $15.7 million in Q1 2026, from $218.4 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $218.4 million in Q4 2025 to a low of $239000.0 in Q2 2022.
- A 5-year average of $30.8 million and a median of $4.7 million in 2024 frame the typical range for Receivables - Net.
- The widest YoY moves for Receivables - Net: up 26278.67% in 2022, down 86.25% in 2022.
- Tracing ARWR's Receivables - Net over 5 years: stood at $39.6 million in 2022, then tumbled by 96.11% to $1.5 million in 2023, then soared by 62.44% to $2.5 million in 2024, then jumped by 8634.16% to $218.4 million in 2025, then slumped by 92.82% to $15.7 million in 2026.
- The last three Receivables - Net figures came in at $15.7 million (Q1 2026), $218.4 million (Q4 2025), and $6.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Arrowhead Pharmaceuticals | 12.23 Bn | 10.63 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.26 Mn |
| Jun 30, 2026 | 15.26 Mn |
| Mar 31, 2026 | 15.69 Mn |
| Mar 31, 2026 | 15.69 Mn |
| Dec 31, 2025 | 218.35 Mn |
| Dec 31, 2025 | 218.35 Mn |
| Sep 30, 2025 | 6.82 Mn |
| Sep 30, 2025 | 6.82 Mn |
| Jun 30, 2025 | 9.70 Mn |
| Jun 30, 2025 | 9.70 Mn |
| Mar 31, 2025 | 2.37 Mn |
| Mar 31, 2025 | 2.37 Mn |
| Dec 31, 2024 | 2.50 Mn |
| Dec 31, 2024 | 2.50 Mn |
| Jun 30, 2023 | 1.54 Mn |
| Jun 30, 2023 | 1.54 Mn |
| Mar 31, 2023 | 70.00 Mn |
| Mar 31, 2023 | 70.00 Mn |
| Dec 31, 2022 | 39.57 Mn |
| Dec 31, 2022 | 39.57 Mn |